Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe disease or impaired antibody and T-cell responses in people with rebound symptoms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216730 | PMC |
| http://dx.doi.org/10.1101/2022.06.16.22276392 | DOI Listing |
Publication Analysis
Top Keywords
clinical virologic
8
clinical rebound
8
rebound nirmatrelvir/ritonavir
8
nirmatrelvir/ritonavir treatment
8
covid-19 redux
4
clinical
4
redux clinical
4
virologic immunologic
4
immunologic evaluation
4
evaluation clinical
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!